Copeland Capital Management LLC Has $22.48 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Copeland Capital Management LLC reduced its position in Eli Lilly and Company (NYSE:LLY) by 3.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 25,369 shares of the company’s stock after selling 994 shares during the quarter. Copeland Capital Management LLC’s holdings in Eli Lilly and Company were worth $22,476,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of LLY. CGN Advisors LLC grew its stake in Eli Lilly and Company by 1.4% during the first quarter. CGN Advisors LLC now owns 1,001 shares of the company’s stock worth $779,000 after purchasing an additional 14 shares during the period. Central Valley Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the 1st quarter worth approximately $245,000. Annex Advisory Services LLC increased its stake in shares of Eli Lilly and Company by 14.1% in the 1st quarter. Annex Advisory Services LLC now owns 4,332 shares of the company’s stock valued at $3,370,000 after acquiring an additional 535 shares in the last quarter. Fermata Advisors LLC lifted its position in shares of Eli Lilly and Company by 27.8% during the 1st quarter. Fermata Advisors LLC now owns 1,113 shares of the company’s stock valued at $866,000 after acquiring an additional 242 shares during the period. Finally, Dynamic Advisor Solutions LLC boosted its stake in Eli Lilly and Company by 2.8% during the first quarter. Dynamic Advisor Solutions LLC now owns 15,381 shares of the company’s stock worth $11,966,000 after acquiring an additional 417 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $906.13 on Tuesday. The stock has a 50 day moving average of $921.65 and a 200 day moving average of $859.57. The company has a market capitalization of $861.19 billion, a price-to-earnings ratio of 133.45, a PEG ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a 12 month low of $547.61 and a 12 month high of $972.53. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $1.28. The firm had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. As a group, sell-side analysts forecast that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

LLY has been the topic of several research reports. Barclays upped their price objective on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a report on Wednesday, July 10th. Sanford C. Bernstein started coverage on Eli Lilly and Company in a report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price target on the stock. BMO Capital Markets raised their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Bank of America increased their target price on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, Guggenheim boosted their price target on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $1,002.24.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.